Abstract:All-trans-retinoic acid (ATRA), the biologically most active metabolite of vitamin A, plays a major role in the regulation of cellular differentiation and proliferation, and it is also an important pharmacological agent particularly used in the treatment of cancer, skin, neurodegenerative and autoimmune diseases. However, ATRA is very easy to be metabolized into 4-hydroxyl-RA in vivo by CYP26A1, an inducible cytochrome P450 enzyme, eventually into more polar metabolites. Therefore, it is vital to develop specific retinoic acid metabolism blocking agents (RAMBAs) to inhibit the metabolic enzyme CYP26A1 in the treatment of relevant diseases aforementioned.In this study, CYP26A1 and its interactions with retinoic acid-competitive metabolism blocking agents were investigated by a combined ligand- and structure-based approach. First, since the crystal structure of CYP26A1 protein has not been determined, we constructed the 3D structure of CYP26A1 using homology modeling. In order to achieve a deeper insight into the mode of action of RAMBAs in the active site, the molecular superimposition model and the common feature pharmacophore model were constructed, and molecular docking was performed. The molecular superimposition model is composed of three features: the main chain groups, side chain groups, and azole groups. The common feature pharmacophore model consists of five chemical features: four hydrophobic groups and one hydrogen acceptor (HHHHA). The results of molecular docking show that the characteristic groups of RAMBAs were mapped into three different active pockets, respectively.A structure-activity relationship (SAR) was obtained by a combination of the molecular superimposition and docking results with the pharmacophore model. This study gives more insight into the interaction model inside the CYP26A1 active site and provides guidance for the design of more potent and possibly more selective RAMBAs. (C) 2014 Elsevier Inc. All rights reserved.

Rational design and virtual screening identify mimetics of the RXR agonist valerenic acid

Structure basis of bigelovin as a selective RXR agonist with a distinct binding mode.

Structural Fusion of Natural and Synthetic Ligand Features Boosts RXR Agonist Potency

Structure-Guided Design of a Highly Potent Partial RXR Agonist with Superior Physicochemical Properties

Structure-guided design of a highly potent RXR agonist with superior physicochemical properties

A Structure-based Approach to Retinoid X Receptor-α Inhibition

Danthron Functions as a Retinoic X Receptor Antagonist by Stabilizing Tetramers of the Receptor

Molecular Recognition of CYP26A1 Binding Pockets and Structure–activity Relationship Studies for Design of Potent and Selective Retinoic Acid Metabolism Blocking Agents

Oxaprozin Analogues as Selective RXR Agonists with Superior Properties and Pharmacokinetics

Virtual Screening and Experimental Validation Identify Novel Modulators of Nuclear Receptor RXRα from Drugbank Database.

Recent Progress in the Design and Discovery of RXR Modulators Targeting Alternate Binding Sites of the Receptor

Identification of a New RXRα Antagonist Targeting the Coregulator-Binding Site.

A review of the molecular design and biological activities of RXR agonists

Therapeutic modulation of retinoid X receptors – SAR and therapeutic potential of RXR ligands and recent patents

Discovery of novel RARα agonists using pharmacophore-based virtual screening, molecular docking, and molecular dynamics simulation studies

A Three-Dimensional Pharmacophore Model for RXRα Agonists

Discovery of small molecules from natural compound databases as potent retinoid X alpha receptor agonists to treat Alzheimer's disease

Activity Screening of Fatty Acid Mimetic Drugs Identified Nuclear Receptor Agonists

Discovery of Atorvastatin As a Tetramer Stabilizer of Nuclear Receptor RXRα Through Structure-Based Virtual Screening.

Binding Affinity and Efficacy-Based Pharmacophore Modeling Studies of Retinoic Acid Receptor Alpha Agonists and Virtual Screening for Potential Agonists from NCI

In Silico Identification of Small Molecules As Novel LXR Agonists for the Treatment of Cardiovascular Disease and Cancer